Macrophages are known to undergo apoptosis during the resolution of inflammation in the lungs, however the mechanisms that regulate macrophage cell death are not known. The appropriate time frame during which macrophages must be removed to resolve inflammation and complete tissue repair also remains unknown. Addressing these gaps in knowledge is of significant importance since persistence of macrophages in inflammatory lesions is associated with tissue injury, abnormal tissue repair and even fibrosis. Our data show that activation of the death receptor, Fas, drives the apoptosis of recruited macrophages in self-limited models of acute lung injury and that macrophage apoptosis is reduced in non-resolving models of acute lung injury (ALI). Based on our preliminary data, we hypothesize that the anti-apoptotic molecule, cellular FLICE inhibitory protein (c-FLIP) is a critical regulator of macrophage apoptosis, and that c-FLIP prevents appropriately timed macrophage apoptosis in non-resolving forms of acute lung injury. This hypothesis will be tested in mouse models of ALI and in macrophages obtained from human subjects with the acute respiratory distress syndrome. Mouse models of ALI will also be used to determine the optimal time during which macrophages must be cleared from the lungs to terminate inflammation and the pathologic consequences of delayed macrophage apoptosis. Achieving the aims of this proposal will provide important insights into the biologic mechanisms that regulate the termination of inflammation and affect tissue repair, paving the way for novel therapies to treat non-resolving ALI and other forms of inflammatory lung disease.
Lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), affect over 190,000 individuals in the United States each year, accounting for over 75,000 deaths, 3.6 million hospital days and $350 million in direct health care costs. During ALI there is massive expansion of macrophages in the lungs. We believe that programmed cell death (apoptosis) of these cells is required for recovery from ALI and that scarring develops in the lungs when macrophages are resistant to cell death. This proposal will help identify the mechanisms that underlie acute lung injury and pave the way for novel therapies for this disease.
|Janssen, William J; Stefanski, Adrianne L; Bochner, Bruce S et al. (2016) Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions. Eur Respir J 48:1201-1214|
|Desch, A Nicole; Gibbings, Sophie L; Goyal, Rajni et al. (2016) Flow Cytometric Analysis of Mononuclear Phagocytes in Nondiseased Human Lung and Lung-Draining Lymph Nodes. Am J Respir Crit Care Med 193:614-26|
|McCubbrey, Alexandra L; Nelson, Joshua D; Stolberg, Valerie R et al. (2016) MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. J Immunol 196:1366-75|
|Janssen, William J; Bratton, Donna L; Jakubzick, Claudia V et al. (2016) Myeloid Cell Turnover and Clearance. Microbiol Spectr 4:|
|McCubbrey, Alexandra L; Barthel, Lea; Mould, Kara J et al. (2016) Selective and inducible targeting of CD11b+ mononuclear phagocytes in the murine lung with hCD68-rtTA transgenic systems. Am J Physiol Lung Cell Mol Physiol 311:L87-L100|
|Kiwamoto, Takumi; Katoh, Toshihiko; Evans, Christopher M et al. (2015) Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis. J Allergy Clin Immunol 135:1329-40.e1-9|
|Evans, Christopher M; Raclawska, Dorota S; Ttofali, Fani et al. (2015) The polymeric mucin Muc5ac is required for allergic airway hyperreactivity. Nat Commun 6:6281|
|Zemans, Rachel L; Henson, Peter M; Henson, Jan E et al. (2015) Conceptual approaches to lung injury and repair. Ann Am Thorac Soc 12 Suppl 1:S9-15|
|Yunt, Zulma X; Solomon, Joshua J (2015) Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am 41:225-36|
|Ghosh, Moumita; Dwyer-Nield, Lori D; Kwon, Jennifer B et al. (2015) Tracheal dysplasia precedes bronchial dysplasia in mouse model of N-nitroso trischloroethylurea induced squamous cell lung cancer. PLoS One 10:e0122823|
Showing the most recent 10 out of 27 publications